In the STAREE trial — a double-blind, randomized, placebo-controlled study of 9,971 community-dwelling Australians aged 70+ with no prior cardiovascular disease, diabetes, or dementia — atorvastatin 40 mg daily produced a striking 30% relative reduction in major cardiovascular events over a median 5.9 years (HR 0.70; 95% CI 0.61–0.82; P<0.001), cutting event rates from 15.5 to 10.9 per 1,000 person-years. However, the composite of all-cause death, dementia, or persistent physical disability was not significantly reduced (HR 0.94; 95% CI 0.84–1.05; P=0.25). Serious adverse events were equally distributed at 2.7%, though musculoskeletal, hepatobiliary, and diabetes-related side effects were modestly more frequent in the statin arm.
This is a paradigm-clarifying result, not merely confirmatory. For decades, guidelines have been ambivalent about primary prevention statins in older adults, partly because absolute cardiovascular benefit was assumed to be offset by competing mortality risks and polypharmacy burden. STAREE directly tests that assumption in a large, well-powered cohort. The cardiovascular benefit is unambiguous and clinically meaningful. Yet the failure to extend disability-free survival — the outcome older adults arguably care most about — is sobering. It suggests cardiovascular protection alone does not translate into broader healthspan gains at this life stage, possibly because dementia and non-cardiac causes of disability dominate outcomes after age 70. Clinicians should weigh this evidence carefully: statins demonstrably reduce heart attacks and strokes in healthy older adults, but patients seeking to preserve function and independence may need realistic expectations about the scope of that benefit.